Published August 14, 2025 | Version v1
Journal article Open

Targeted Epigenome Editing with CRISPR Technologies: Transforming Cancer Treatment Strategies

Contributors

Hosting institution:

Description

Background: Cancer remains a leading global health challenge, with nearly 10 million deaths in 2020. Traditional therapies like chemotherapy and radiation often face limitations including systemic toxicity, acquired resistance, and suboptimal tumor targeting. The advent of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas9 technology has revolutionized genetic research by enabling precise gene editing. Its adaptation for epigenetic modulation presents novel opportunities to reversibly regulate gene expression in cancer without introducing permanent deoxyribonucleic acid (DNA) alterations.

Objective: This literature review evaluates the therapeutic potential of CRISPR-based epigenetic editing in cancer treatment and examines recent clinical studies that inform its translational prospects.

Methodology: A systematic literature search was conducted using PubMed for clinical trials and randomized controlled trials published between January 2020 and June 2025, focusing on CRISPR, epigenetics, and cancer therapy. Five clinical studies met inclusion criteria and were reviewed following preferred reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines.

Results: The reviewed studies highlight genetic mutations and epigenetic alterations in cancers such as human epidermal growth factor receptor 2 (HER2)-mutant breast cancer, prostate cancer, and peripheral T-cell lymphomas. CRISPR-dCas9 fusion tools and ribonucleic acid (RNA)-targeting systems like Cas13 offer precision in modulating gene expression, potentially overcoming drug resistance and reactivating tumor suppressors. However, efficient delivery, specificity, and safety remain significant barriers.

Conclusion: CRISPR-mediated epigenetic editing holds transformative potential in precision oncology by enabling targeted, reversible gene regulation. Future research must address delivery technologies, off-target risks, and clinical validation to advance CRISPR applications in cancer therapeutics.

Files

Files (88.0 kB)

Name Size Download all
md5:6e550aab459f8d1bf70bc64cbbec5520
88.0 kB Download

Additional details

Identifiers

URL
https://journal.medtigo.com/targeted-epigenome-editing-with-crispr-technologies-transforming-cancer-treatment-strategies/

Related works

Is published in
Journal: 3065-4661 (ISSN)

Dates

Accepted
2025-08-14

References

  • 1. Pradeep KRK, Raj KB, Shrivastava SP, et al. An Observational Study on Drug-Related Problems in the Treatment of Cancer Patients. medtigo J Med. 2025;3(2):e3062326. doi:10.63096/medtigo3062326 Crossref
  • 2. Irfan M, Majeed H, Iftikhar T, Ravi PK. A review on molecular scissoring with CRISPR/Cas9 genome editing technology. Toxicol Res (Camb). 2024;13(4):tfae105. doi:10.1093/toxres/tfae105 PubMed | Crossref | Google Scholar
  • 3. Zhang C, Quan R, Wang J. Development and application of CRISPR/Cas9 technologies in genomic editing. Hum Mol Genet. 2018;27(R2):R79-88. doi:10.1093/hmg/ddy120 PubMed | Crossref | Google Scholar
  • 4. Sun L, Zheng P, Sun J, Wendisch VF, Wang Y. Genome-scale CRISPRi screening: A powerful tool in engineering microbiology. Eng Microbiol. 2023;3(3):100089. doi:10.1016/j.engmic.2023.100089 PubMed | Crossref | Google Scholar
  • 5. Nelles DA, Fang MY, O'Connell MR, et al. Programmable RNA Tracking in Live Cells with CRISPR/Cas9. Cell. 2016;165(2):488-496. doi:10.1016/j.cell.2016.02.054 PubMed | Crossref | Google Scholar
  • 6. Zhen S, Lu JJ, Wang LJ, et al. In Vitro and In Vivo Synergistic Therapeutic Effect of Cisplatin with Human Papillomavirus16 E6/E7 CRISPR/Cas9 on Cervical Cancer Cell Line. Transl Oncol. 2016;9(6):498-504. doi:10.1016/j.tranon.2016.10.002 PubMed | Crossref | Google Scholar
  • 7. Seeger C, Sohn JA. Complete Spectrum of CRISPR/Cas9-induced Mutations on HBV cccDNA. Mol Ther. 2016;24(7):1258-1266. doi:10.1038/mt.2016.94 PubMed | Crossref | Google Scholar
  • 8. Kennedy EM, Bassit LC, Mueller H, et al. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease. Virology. 2015;476:196-205. doi:10.1016/j.virol.2014.12.001 PubMed | Crossref | Google Scholar
  • 9. Zhu W, Xie K, Xu Y, et al. CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res. 2016;217:125-132. doi:10.1016/j.virusres.2016.04.003 PubMed | Crossref | Google Scholar
  • 10. Yang L, Achreja A, Yeung TL, et al. Targeting Stromal Glutamine Synthetase in Tumors Disrupts Tumor Microenvironment-Regulated Cancer Cell Growth. Cell Metab. 2016;24(5):685-700. doi:10.1016/j.cmet.2016.10.011 PubMed | Crossref | Google Scholar
  • 11. Zambirinis CP, Miller G. Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. Trends Mol Med. 2017;23(5):465-481. doi:10.1016/j.molmed.2017.03.003 PubMed | Crossref | Google Scholar
  • 12. Zheng M, Li H, Gao Y, Brigstock DR, Gao R. Vitamin D3 analogue calcipotriol inhibits the profibrotic effects of transforming growth factor- β1 on pancreatic stellate cells. Eur J Pharmacol. 2023;957:176000. doi:10.1016/j.ejphar.2023.176000 PubMed | Crossref | Google Scholar
  • 13. Neggers JE, Vercruysse T, Jacquemyn M, et al. Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing. Chem Biol. 2015;22(1):107-116. doi:10.1016/j.chembiol.2014.11.015 PubMed | Crossref | Google Scholar
  • 14. Tzelepis K, Koike-Yusa H, De Braekeleer E, et al. A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia. Cell Rep. 2016;17(4):1193-1205. doi:10.1016/j.celrep.2016.09.079 PubMed | Crossref | Google Scholar
  • 15. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461. doi:10.1016/j.ccell.2015.03.001 PubMed | Crossref | Google Scholar
  • 16. Ahmed S, Wan Azizan WAS, Nazri FR, Hatta MAM. Harnessing CRISPR/Cas9 system to engineer disease resistance in solanaceous crops: current progress and future prospects. Hortic Sci (Prague). 2025;52(1):1-14. doi:10.17221/19/2024-HORTSCI Crossref | Google Scholar
  • 17. Aubrey BJ, Kelly GL, Kueh AJ, et al. An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in vivo. Cell Rep. 2015;10(8):1422-1432. doi:10.1016/j.celrep.2015.02.002 PubMed | Crossref | Google Scholar
  • 18. Antal CE, Hudson AM, Kang E, et al. Cancer-associated protein kinase C mutations reveal kinase's role as tumor suppressor. Cell. 2015;160(3):489-502. doi:10.1016/j.cell.2015.01.001 PubMed | Crossref | Google Scholar
  • 19. Hoppe-Seyler K, Bossler F, Braun JA, Herrmann AL, Hoppe-Seyler F. The HPV E6/E7 Oncogenes: Key Factors for Viral Carcinogenesis and Therapeutic Targets. Trends Microbiol. 2018;26(2):158-168. doi:10.1016/j.tim.2017.07.007 PubMed | Crossref | Google Scholar
  • 20. Anand U, Dey A, Chandel AKS, et al. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics. Genes Dis. 2022;10(4):1367-1401. doi:10.1016/j.gendis.2022.02.007 PubMed | Crossref | Google Scholar
  • 21. Roychowdhury S, Chinnaiyan AM. Translating cancer genomes and transcriptomes for precision oncology. CA Cancer J Clin. 2016;66(1):75-88. doi:10.3322/caac.21329 PubMed | Crossref | Google Scholar
  • 22. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: Current status and future directions. CA Cancer J Clin. 2015;65(5):345-383. doi:10.3322/caac.21287 PubMed | Crossref | Google Scholar
  • 23. Sachdeva M, Sachdeva N, Pal M, et al. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer. Cancer Gene Ther. 2015;22(11):509-517. doi:10.1038/cgt.2015.54 PubMed | Crossref | Google Scholar
  • 24. Ansori AN, Antonius Y, Susilo RJ, et al. Application of CRISPR-Cas9 genome editing technology in various fields: A review. Narra J. 2023;3(2):e184. doi:10.52225/narra.v3i2.184 PubMed | Crossref | Google Scholar
  • 25. Lee M. Deep learning in CRISPR-Cas systems: a review of recent studies. Front Bioeng Biotechnol. 2023;11:1226182. doi:10.3389/fbioe.2023.1226182 PubMed | Crossref | Google Scholar
  • 26. Charlier J, Nadon R, Makarenkov V. Accurate deep learning off-target prediction with novel sgRNA-DNA sequence encoding in CRISPR-Cas9 gene editing. Bioinformatics. 2021;37(16):2299-2307. doi:10.1093/bioinformatics/btab112 PubMed | Crossref | Google Scholar
  • 27. Okines AFC, Curigliano G, Mizuno N, et al. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med. 2025;31(3):909-916. doi:10.1038/s41591-024-03462-0 PubMed | Crossref | Google Scholar
  • 28. Connolly RM, Zhao F, Miller KD, et al. E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. J Clin Oncol. 2021;39(28):3171-3181. doi:10.1200/JCO.21.00944 PubMed | Crossref | Google Scholar
  • 29. Abida W, Hahn AW, Shore N, et al. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide. Clin Cancer Res. 2024;30(6):1111-1120. doi:10.1158/1078-0432.CCR-23-3508 PubMed | Crossref | Google Scholar
  • 30. Horwitz SM, Nirmal AJ, Rahman J, et al. Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial. Nat Med. 2024;30(9):2517-2527. doi:10.1038/s41591-024-03076-6 PubMed | Crossref | Google Scholar
  • 31. Vaishampayan UN, Muzaffar J, Winer I, et al. Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1). J Immunother Cancer. 2024;12(11):e010143. doi:10.1136/jitc-2024-010143 PubMed | Crossref | Google Scholar